Literature DB >> 33190583

Cannabinoids in the management of frontotemporal dementia: a case series.

Ganesh Gopalakrishna1,2, Yazhini Srivathsal1,3, Gurmehr Kaur1.   

Abstract

Background: Frontotemporal dementia (FTD) is characterized by progressive deterioration in behaviors, executive function and/or language. The behavioral variant (Bv) is characterized by disinhibition and obsessive/compulsive behaviors. These symptoms are sometimes resistant to medications. This series examines patients suffering with treatment-resistant Bv-FTD who were prescribed cannabinoid and related compounds for other indications. Case presentation: Three FTD cases from a dementia clinic were identified. These patients had disability due to behavior despite typical pharmacologic management. These patients were prescribed marijuana for comorbidities (anxiety, insomnia and pain). In all cases, use of cannabinoid products showed significant improvements in behavior and in the primary indication for prescription.
Conclusion: Review of these cases demonstrates potential for the use of cannabinoids in the management of treatment-resistant Bv-FTD.

Entities:  

Keywords:  CBD; FTD; behavioral variant FTD; cannabinoids; dementia; frontotemporal dementia; medical marijuana; tetrahydrocannabinol

Year:  2020        PMID: 33190583     DOI: 10.2217/nmt-2020-0048

Source DB:  PubMed          Journal:  Neurodegener Dis Manag        ISSN: 1758-2024


  1 in total

1.  Medical cannabinoids for treatment of neuropsychiatric symptoms in dementia: a systematic review.

Authors:  Florindo Stella; Leandro C Lane Valiengo; Vanessa J R de Paula; Carlos Augusto de Mendonça Lima; Orestes V Forlenza
Journal:  Trends Psychiatry Psychother       Date:  2021-07-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.